Clene (NASDAQ:CLNN) said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS. In a fireside chat at the Lytham Partners Fall 2026 Investor Confe
Detailed price information for Clene Inc (CLNN-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.